Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 2/20 | 1.00 |
| ▸ | F3 | P13726 | 2/20 | 1.00 |
| ▸ | MGAM | O43451 | 3/20 | 0.86 |
| ▸ | GAA | P10253 | 3/20 | 0.86 |
| ▸ | SI | P14410 | 3/20 | 0.86 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | MIF | P14174 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | F2 | P00734 | 3/20 | 0.62 |
| ▸ | F10 | P00742 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473217 | 1.00 | CYP2C9 (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL5585182 | 1.00 | CYP2C9 (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL5585354 | 0.92 | CYP1A2 (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL14473242 | 0.92 | CYP1A2 (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL5585355 | 0.92 | CYP1A2 (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL1524260 | 0.86 | CYP2C9 (0.76) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL9302118 | 0.86 | CYP2C9 (0.76) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL1524262 | 0.86 | CYP2C9 (0.76) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL17077347 | 0.83 | EGFR (1.00) | CYP2C9HSD11B1F3MGAMGAA | |
| SCHEMBL17077345 | 0.83 | EGFR (1.00) | CYP2C9HSD11B1F3MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | claimed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | claimed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| EP-1247797-B1 | Cycloalkanone Derivates | MERCK PATENT GMBH (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-6939479-B2 | Cycloalkanone derivatives | MERCK PATENT GMBH (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20030080321-A1 | Cycloalkanone derivatives | MERCK KGAA (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1247797-A2 | Cycloalkanone Derivates | MERCK PATENT GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-6043334-A | USEFUL FOR PRODUCTION OF CROSSLINKED POLYCARBONATE RESINS; ELECTROPHOTOGRAPHIC PHOTORECEPTORS, WHICH HAVE PHOTOSENSITIVE LAYER CONTAINING CROSSLINKED POLYCARBONATE RESINS | IDEMITSU KOSAN CO., LTD. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0866083-A1 | POLYCARBONATE RESIN, CROSSLINKED POLYCARBONATE RESIN AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | CYP2C9 4847/4885HSD11B1 1739/4885F3 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.